Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Vijay Patil; Sravan Kumar; Vanita Noronha; Nandini Menon; Kavita Prakash Nawale; Mitali Alone; Gopichand Waratkar; Sachin Dhumal; Atanu Bhattacharjee; Kumar Prabhash

doi:10.1016/j.oraloncology.2022.106085

Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Vijay Patil, Sravan Kumar, Vanita Noronha, Nandini Menon, Kavita Prakash Nawale, Mitali Alone, Gopichand Waratkar, Sachin Dhumal, Atanu Bhattacharjee, Kumar Prabhash (Lead / Corresponding author)

Population Health and Genomics

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	106085
Number of pages	4
Journal	Oral Oncology
Volume	134
Early online date	18 Sept 2022
DOIs	https://doi.org/10.1016/j.oraloncology.2022.106085
Publication status	Published - Nov 2022

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Docetaxel/therapeutic use
Head and Neck Neoplasms/drug therapy
Humans
Neoplasm Recurrence, Local/drug therapy
Taxoids/therapeutic use
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2022.106085

Cite this

Patil, V., Kumar, S., Noronha, V., Menon, N., Nawale, K. P., Alone, M., Waratkar, G., Dhumal, S., Bhattacharjee, A., & Prabhash, K. (2022). Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncology, 134, Article 106085. https://doi.org/10.1016/j.oraloncology.2022.106085

@article{d1e64eac8a6049fbaaa96052bdaea8da,

title = "Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Docetaxel/therapeutic use, Head and Neck Neoplasms/drug therapy, Humans, Neoplasm Recurrence, Local/drug therapy, Taxoids/therapeutic use, Treatment Outcome",

author = "Vijay Patil and Sravan Kumar and Vanita Noronha and Nandini Menon and Nawale, {Kavita Prakash} and Mitali Alone and Gopichand Waratkar and Sachin Dhumal and Atanu Bhattacharjee and Kumar Prabhash",

year = "2022",

month = nov,

doi = "10.1016/j.oraloncology.2022.106085",

language = "English",

volume = "134",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier",

}

Patil, V, Kumar, S, Noronha, V, Menon, N, Nawale, KP, Alone, M, Waratkar, G, Dhumal, S, Bhattacharjee, A & Prabhash, K 2022, 'Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer', Oral Oncology, vol. 134, 106085. https://doi.org/10.1016/j.oraloncology.2022.106085

TY - JOUR

T1 - Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

AU - Patil, Vijay

AU - Kumar, Sravan

AU - Noronha, Vanita

AU - Menon, Nandini

AU - Nawale, Kavita Prakash

AU - Alone, Mitali

AU - Waratkar, Gopichand

AU - Dhumal, Sachin

AU - Bhattacharjee, Atanu

AU - Prabhash, Kumar

PY - 2022/11

Y1 - 2022/11

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Docetaxel/therapeutic use

KW - Head and Neck Neoplasms/drug therapy

KW - Humans

KW - Neoplasm Recurrence, Local/drug therapy

KW - Taxoids/therapeutic use

KW - Treatment Outcome

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85138109343&origin=inward

U2 - 10.1016/j.oraloncology.2022.106085

DO - 10.1016/j.oraloncology.2022.106085

M3 - Letter

C2 - 36126602

SN - 1368-8375

VL - 134

JO - Oral Oncology

JF - Oral Oncology

M1 - 106085

ER -

Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Keywords

UN SDGs

Access to Document

Other files and links

Cite this